Octave Specialty Group, Inc.

NYSE:OSG 株式レポート

時価総額：US$262.0m

Octave Specialty Group 将来の成長

Future 基準チェック /16

Octave Specialty Groupは、71.8%と18.1%でそれぞれ年率71.8%で利益と収益が成長すると予測される一方、EPSはgrowで71.4%年率。

主要情報

71.8%

収益成長率

71.37%

EPS成長率

Insurance 収益成長2.0%
収益成長率18.1%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日07 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 13

OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential

Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.
ナラティブの更新 • Apr 22

OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential

Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).
ナラティブの更新 • Apr 07

OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential

Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).
ナラティブの更新 • Mar 23

OSG: Share Repurchases Will Support Future Upside Potential

Analysts now hold their price target for Octave Specialty Group at $12.00, reflecting slightly updated assumptions for revenue growth, profit margins, discount rate, and future P/E that fine tune rather than overhaul their prior view. What's in the News Completed share repurchase program with a total of 4,371,886 shares bought back for $42.45 million, representing 9.33% of shares under the buyback announced on November 12, 2024 (Key Developments).
ナラティブの更新 • Mar 09

OSG: Share Repurchases And Auditor Shift Will Support Future Upside Potential

Analysts have reduced their price target on Octave Specialty Group from $15.00 to $12.00, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Completed share repurchase of 4,371,886 shares in total, representing 9.33% of shares, for $41.69 million under the buyback announced on November 12, 2024.
ナラティブの更新 • Feb 22

OSG: Auditor Transition And Execution Will Support Future Upside Potential

Analysts have adjusted their price target on Octave Specialty Group to $15.00. This change reflects updated assumptions around slightly higher projected revenue growth, a modestly stronger profit margin, and a lower future P/E multiple.
ナラティブの更新 • Feb 07

OSG: ArmadaCare Execution And Organic Expansion Will Support Future Upside Potential

Analysts have raised their price target on Octave Specialty Group to $15 from $10, citing updated models that incorporate recent earnings, higher assumed organic growth, and the impact of the ArmadaCare deal. Analyst Commentary While the new US$15 price target signals higher modeled value for Octave Specialty Group, not all of the commentary behind the scenes is purely optimistic.
ナラティブの更新 • Jan 24

OSG: Higher Growth Assumptions And ArmadaCare Integration Will Drive Future Upside

Narrative Update Analysts have lifted their price target on Octave Specialty Group to US$15 from US$10, citing refreshed models that factor in higher assumed organic growth, the ArmadaCare acquisition and recent quarterly performance. Analyst Commentary While the higher US$15 target reflects more constructive modeling around organic growth and the ArmadaCare acquisition, not all commentary skews optimistic.
ナラティブの更新 • Jan 09

OSG: Earnings Beat And ArmadaCare Integration Will Support Long-Term Share Gains

Analysts have raised their price target on Octave Specialty Group by $5 to $15, citing updated models that incorporate Q3 earnings, revised assumptions for organic growth, and the expected impact of the ArmadaCare transaction. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated Q3 earnings model as support for the new US$15 price target, arguing that current valuation better reflects Octave Specialty Group's recent financial results.
ナラティブの更新 • Dec 25

OSG: Earnings Beat And Deals Will Drive Long-Term Shareholder Upside

Analysts raised their price target for Octave Specialty Group by $5, increasing it to $15 from $10. They cited updated models that reflect stronger assumed organic growth following an earnings beat and recent strategic transactions, which they believe support a path to sustained elevated expansion.
ナラティブの更新 • Dec 11

OSG: Q3 Earnings Beat Will Support Long-Term Shareholder Value Expansion

Analysts raised their price target on Octave Specialty Group to $15 from $10, citing updated models that reflect stronger than expected Q3 performance, higher assumed organic growth, and incremental upside from recent strategic deals. Analyst Commentary Analysts note that the revised price target for Octave Specialty Group is grounded in tangible improvements to the company’s growth profile, as well as rising confidence in management’s ability to execute on recent strategic initiatives.
ナラティブの更新 • Nov 27

OSG: Sustained Organic Expansion Will Drive Long-Term Shareholder Value

Analysts have raised their price target for Octave Specialty Group, increasing it by $5 to reflect stronger than expected organic growth and recent strategic acquisitions. Analyst Commentary Following the recent price target increase, analysts have provided additional context regarding their views on Octave Specialty Group's prospects.
ナラティブの更新 • Nov 13

AMBC: Revenue Momentum and Armada Acquisition Will Drive Further Share Upside

Analysts have raised their price target for Octave Specialty Group from $14.67 to $16.33. They cite stronger projected revenue growth and improved profitability metrics in their updated outlook.
Seeking Alpha • Oct 03

Ambac: Surprise Acquisition Changes Outlook (Rating Downgrade)

Summary Ambac is downgraded to Hold following the surprise $250M ArmadaCare acquisition after selling its legacy guarantee business. The new deal adds product diversification and potential growth, but reintroduces debt and increases risk to the balance sheet. Management maintains 2028 adjusted EBITDA guidance at $80M–$90M, despite the significant size of the ArmadaCare acquisition. I recommend waiting for a lower entry price below $7 or more clarity in Q3 results before considering AMBC a Buy again. Read the full article on Seeking Alpha
User avatar
新しいナラティブ • Jul 20

US Infrastructure Spending And Automation Will Unlock Insurance Potential

Diversification into specialty insurance and tech-driven operations is improving revenue stability, earnings quality, and operational efficiency.
Seeking Alpha • Mar 01

Ambac: Despite EPS Miss, It's A Growth Company

Summary Ambac Financial Group saw a stock decline after an earnings miss for Q4. Such a sell-off overlooks the fundamental improvements: profitable underwriting and the build-out of a higher-ROE distribution platform. The sale of the legacy business remains to be approved by Wisconsin, creating a thorn in AMBC's side for the moment. Management, however, was eager about the growth ahead; the current price is a small P/E for earnings in just a few years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 27

Ambac Financial: Don't Get Lost In The Weeds; It's Working

Summary Ambac Financial Group has shifted from guarantee insurance to specialty property-casualty insurance and distribution. Despite a drop in tangible book value per share, the sale of the legacy business and recent acquisitions are expected to improve financials and boost earnings. Ambac Financial faces risks from recent hurricanes and potential delays in the legacy business sale approval, but overall outlook remains positive. I maintain a Buy rating on AMBC stock, believing Ambac's turnaround strategy will lead to better capitalization and improved earnings, offering a favorable risk-reward asymmetry. Read the full article on Seeking Alpha
Seeking Alpha • Jul 30

Ambac Financial: Unbundling The Recent Sale And The New Acquisition

Summary Ambac sold its Financial Guarantee business to Oaktree at a disappointing valuation, causing a 20% drop in stock price. The company reinvested proceeds into acquiring a majority stake in Beat Capital Partners for $280 million at a generous valuation, raising concerns among investors. Despite the negative stock reaction, a new valuation framework suggests a fair value per share of around $15, indicating a 20% upside potential. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

Ambac: Finally Shaking Off The Great Financial Crisis

Summary Ambac Financial Group has undergone a turnaround after the 2008 Financial Crisis, improving its financial position and evolving its business model. The company's balance sheet appears healthy and able to meet upcoming obligations, with a new focus on specialty property-casualty insurance. AMBC is positioning itself to underwrite its products through a technology-driven MGA model, aiming to take advantage of the growing US market with attractive loss ratios. Yet, investors should remember that the discount exists for a reason, given how a recession could particularly affect a company like this. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Ambac: Releasable Liquidity And SOTP Analysis Reveals Upside Potential

Summary Ambac is a complex company with a financial guarantees business and a new specialty P&C insurance business. We run a comparison with MBIA to compute releasable liquidity from the FG business that may be paid out as a special dividend. Ambac may benefit from a liquidity release or a sale, but the bulk of its value lies in its new businesses. Read the full article on Seeking Alpha
Seeking Alpha • Sep 24

Ambac Financial Group Inc: Debt Trap Disguised As Value Opportunity

Summary Ambac Financial Group Inc is trading at low multiples but has a significant amount of debt that is impacting its expansion capacities. AMBC operates through two divisions, Everspan and Cirrata, and presents itself as an opportunity in the growing specialty coverage market. The company's high debt levels and inconsistent bottom line make it a risky investment, and the share price is expected to decline further. Read the full article on Seeking Alpha
Seeking Alpha • Jun 14

Ambac Remains Discounted By An Apprehensive Market

Summary Ambac has seen significant price appreciation since the announced settlement with Bank of America and Nomura Holdings. Alongside aggressive growth from Cirrata, shareholders can expect effective organic and inorganic growth from Ambac. Despite these factors, Ambac still trades at a 23% undervaluation, leading me to rate the company a 'buy'. Read the full article on Seeking Alpha
Seeking Alpha • Jan 03

Ambac settles with Nomura, closing financial crisis-era RMBS lawsuits

Ambac Financial Group (NYSE:AMBC) said Tuesday its Assurance Corporation subsidiary (AAC) entered into a settlement agreement with Nomura (NYSE:NMR) that will give AAC $140M. The settlement brings to an end all of Ambac's (AMBC) legacy residential mortgage-backed securities representation and warranty litigation that arose from the 2008 financial crisis. In October, Bank of America (BAC) agreed to pay Ambac $1.8B to settle litigation related to mortgage company Countrywide's collapse during the crisis. The settlement exceeds the amount of recovery recorded on Ambac's (AMBC) Q3 2022 GAAP financial statements attributed to the Nomura (NMR) litigation. As a result, the company will record a gain of ~$43M in its Q4 financial statement. Last month, Street Insider reported that Assured Guaranty (AGO) and Ambac Financial (AMBC) had made bids for rival MBIA (MBI).
分析記事 • May 12

Just In: One Analyst Has Become A Lot More Bullish On Ambac Financial Group, Inc.'s (NYSE:AMBC) Earnings

Celebrations may be in order for Ambac Financial Group, Inc. ( NYSE:AMBC ) shareholders, with the covering analyst...

業績と収益の成長予測

NYSE:OSG - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2027408-25N/AN/A1
12/31/2026369-45N/AN/A1
3/31/2026293-96-50-50N/A
12/31/2025251-117-52-52N/A
9/30/2025254-106-171-171N/A
6/30/2025258-94-50-50N/A
3/31/2025254-87-29-29N/A
12/31/2024241-6511N/A
9/30/2024105-7811N/A
6/30/20241048-32-32N/A
3/31/202411310-23-23N/A
12/31/2023125-203737N/A
9/30/20233251971,3881,388N/A
6/30/20233204711,4251,425N/A
3/31/20232734891,4031,403N/A
12/31/202254-337070N/A
9/30/20222343276464N/A
6/30/20222164-37-37N/A
3/31/2022258-31-82-82N/A
12/31/2021249-29-131-131N/A
9/30/2021245-23-144-144N/A
6/30/2021254-148-146-146N/A
3/31/2021275-153-128-128N/A
12/31/2020156-437-175-175N/A
9/30/2020175-533-182-182N/A
6/30/2020195-359-158-158N/A
3/31/2020217-453-303-303N/A
12/31/2019362-216N/A-311N/A
9/30/2019337-126N/A-421N/A
6/30/2019393-296N/A-496N/A
3/31/2019444-163N/A-446N/A
12/31/2018506186N/A-1,543N/A
9/30/2018629187N/A-1,394N/A
6/30/2018629100N/A-1,367N/A
3/31/2018613102N/A-1,408N/A
12/31/2017567-329N/A-221N/A
9/30/2017551-404N/A-227N/A
6/30/2017577-112N/A-196N/A
3/31/2017576-60N/A11N/A
12/31/201655275N/A830N/A
9/30/2016542557N/A835N/A
6/30/201653264N/A927N/A
3/31/2016584288N/A914N/A
12/31/2015688493N/A92N/A
9/30/2015662560N/A-1,148N/A
6/30/20156851,033N/A-1,105N/A

アナリストによる今後の成長予測

収入対貯蓄率: OSG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OSG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: OSG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OSGの収益 ( 18.1% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: OSGの収益 ( 18.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OSGの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 17:42
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Octave Specialty Group, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Giuliano Anderes BolognaBTIG
Mary KaneCitigroup Inc
Giuliano Anderes BolognaCompass Point Research & Trading, LLC